Tuesday, November 19, 2019 8:51:53 AM
Item 8.01 Other Events.
On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.
BioVie is evaluating the Board’s decision to determine if it will request a rehearing by the Board or appeal the Board’s decision to the U.S. Court of Appeals for the Federal Circuit. This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues on the pending application according to the patent laws of each issuing country.
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000459/bivi-20191115_8k.htm
Recent BIVI News
- The Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming Deadline • PR Newswire (US) • 03/14/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:00:30 PM
- BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI • PR Newswire (US) • 03/11/2024 09:45:00 AM
- Contact The Gross Law Firm by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI) • PR Newswire (US) • 03/07/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 10:10:37 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:28:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 10:28:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:50:52 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/01/2024 10:27:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:40:39 PM
- The Gross Law Firm Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIVI • PR Newswire (US) • 02/26/2024 10:45:00 AM
- The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI • PR Newswire (US) • 02/09/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of BioVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024 - (NASDAQ: BIVI) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of BioVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024 - (NASDAQ: BIVI) • PR Newswire (US) • 01/26/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:15:31 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 09:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 09:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 01:20:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:30:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 05:04:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/29/2023 09:20:39 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM